RUA Life Sciences PLC (LSE:RUA) Share Price

Company Profile

Business description
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
Contact
2 Drummond Crescent
Scotland
IrvineAyrshireKA11 5AN
GBR
T: +44 1294317073
E: [email protected]
https://www.rualifesciences.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2027
Employees
59

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,811.26	110.42	-1.39%
DAX 40	25,371.75	273.29	-1.07%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,725.03	27.85	-0.26%
HKSE	23,076.96	142.28	0.62%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,527.74	380.10	-0.60%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,663.43	93.74	-1.21%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,641.59	16.43	-0.45%